Literature DB >> 15978252

SiRNA strategy against overexpression of extracellular matrix in diabetic retinopathy.

Toshiyuki Oshitari1, David Brown, Sayon Roy.   

Abstract

Increased synthesis of extracellular matrix (ECM) contributes to the development of vascular BM thickening, a prominent abnormality in diabetic retinopathy. RNA interference (RNAi) approach was used in this study to examine the effect of small interfering RNAs (siRNAs) for their ability to inhibit ECM-specific gene overexpression under high glucose condition in rat microvascular endothelial cells (RMECs). Four fibronectin (FN)-siRNAs, three collagen IV (Coll IV)-siRNAs, and four laminin (LM)-siRNAs, a total of 11 siRNAs were screened. RMECs were transfected with 10, 30, or 100 nm of each siRNAs in the presence of 8 microm lipofectin and subjected to analysis 72 hr after transfection. In long-term studies siRNA-transfected cells were examined after 12 days. Two FN siRNAs, two Coll IV siRNAs, and two LM siRNAs significantly reduced the respective target expressions. Findings from this study indicate that high glucose-induced abnormal expression of BM components may contribute to increased vascular permeability. SiRNA may be a useful tool in preventing excess vascular permeability, a characteristic feature of early diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15978252     DOI: 10.1016/j.exer.2005.01.006

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  9 in total

1.  A long-term siRNA strategy regulates fibronectin overexpression and improves vascular lesions in retinas of diabetic rats.

Authors:  Sumon Roy; Sigrid Nasser; Melissa Yee; Dana T Graves; Sayon Roy
Journal:  Mol Vis       Date:  2011-12-06       Impact factor: 2.367

2.  Efficient delivery of NF-κB siRNA to human retinal pigment epithelial cells with hyperbranched cationic polysaccharide derivative-based nanoparticles.

Authors:  Zhenzhen Liu; Haijun Gong; Rui Zeng; Xuan Liang; Li-Ming Zhang; Liqun Yang; Yuqing Lan
Journal:  Int J Nanomedicine       Date:  2015-04-07

Review 3.  Neurodegeneration and Neuroinflammation in Diabetic Retinopathy: Potential Approaches to Delay Neuronal Loss.

Authors:  Joanna Kadłubowska; Lucia Malaguarnera; Piotr Wąż; Katarzyna Zorena
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

4.  High Glucose Increases Binding of Lysyl Oxidase to Extracellular Matrix Proteins: Implications for Diabetic Retinopathy.

Authors:  Ngan-Ha Nguyen; Dongjoon Kim; Sayon Roy
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-04-09       Impact factor: 4.799

Review 5.  Neurovascular Impairment and Therapeutic Strategies in Diabetic Retinopathy.

Authors:  Toshiyuki Oshitari
Journal:  Int J Environ Res Public Health       Date:  2021-12-31       Impact factor: 3.390

Review 6.  Retinal capillary basement membrane thickening: Role in the pathogenesis of diabetic retinopathy.

Authors:  Sayon Roy; Dongjoon Kim
Journal:  Prog Retin Eye Res       Date:  2020-09-18       Impact factor: 21.198

7.  Knockdown of TNF‑α alleviates acute lung injury in rats with intestinal ischemia and reperfusion injury by upregulating IL‑10 expression.

Authors:  Zhen Yang; Xue-Rong Zhang; Qiong Zhao; Sheng-Lan Wang; Liu-Lin Xiong; Piao Zhang; Bing Yuan; Zi-Bing Zhang; Shu-Yuan Fan; Ting-Hua Wang; Yun-Hui Zhang
Journal:  Int J Mol Med       Date:  2018-05-14       Impact factor: 4.101

8.  Upregulation of Lysyl Oxidase Expression in Vitreous of Diabetic Subjects: Implications for Diabetic Retinopathy.

Authors:  Manju L Subramanian; Thor D Stein; Nicole Siegel; Steven Ness; Marissa G Fiorello; Dongjoon Kim; Sayon Roy
Journal:  Cells       Date:  2019-09-21       Impact factor: 6.600

Review 9.  Delivery systems and local administration routes for therapeutic siRNA.

Authors:  Fabiana Testa Moura de Carvalho Vicentini; Lívia Neves Borgheti-Cardoso; Lívia Vieira Depieri; Danielle de Macedo Mano; Thais Fedatto Abelha; Raquel Petrilli; Maria Vitória Lopes Badra Bentley
Journal:  Pharm Res       Date:  2013-01-24       Impact factor: 4.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.